Best Practices in the Treatment and Management of Ovarian Cancer: An In-Depth Look at the Evolving Role of PARP Inhibitors

A continuing medical education activity provided by NAMCP and AAMCN

This activity is an archive of the live session from the 2021 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from July 1, 2021 – August 1, 2022
 

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by educational grants from
GlaxoSmithKline, Merck Sharp & Dohme Corp., and AstraZeneca

Description:
There will be an estimated 21,410 new cases of ovarian cancer this year in the United States, and an estimated 13,770 deaths due to ovarian cancer in the US, according to the American Cancer Society. Ovarian cancer is usually found late, stage 3 or higher, where it has already spread or metastasized to other parts of the abdomen, or worse. This is due in large part to a lack of symptoms during the earlier stages. The five year survival rate is only 45%. Fortunately for patients with ovarian cancer, the treatment paradigm has exploded in the past three years, giving medical directors and clinicians more options in managing patients with ovarian cancer. Leading the way in new options for ovarian cancer are poly (ADP-ribose) polymerase (PARP) inhibitors, which have shown improved efficacy for patients with ovarian cancer. Additionally, new indications for these targeted agents offer expanded options in the maintenance setting in varying lines of therapy. It is important for medical directors, oncologists, and nurses who manage ovarian cancer patient populations to have a solid understanding of the mechanistic rationale for the use of these medications in order to optimize their therapeutic application.

The enzyme poly (ADP-ribose) polymerase (PARP) is a critical component of DNA base excision repair, essential for the repair of single-strand breaks in DNA. If the action of PARP is inhibited in a normal cell, these breaks are converted to double-strand breaks and repaired through the process of homologous recombination. However, in cells with pre-existing defects in the homologous recombination DNA repair pathway, such as in cancer cells harboring BRCA1/2 mutations, inhibition of PARP results in synthetic lethality. Exploitation of this deficiency with PARP inhibitors creates a therapeutic opportunity for tumor cell-specific cell killing. Challenges associated with maximizing therapeutic outcomes with potential PARP inhibitor use in ovarian cancer include selection of optimal testing strategies to personalize care, management of treatment toxicities, and development of evidence-based sequencing and combination strategies. With new indications for these newer treatments have been approved, including new indications, making the need for education extremely important. It is for this reason that we must educate healthcare professionals on the latest clinical data, updated guidelines, and management strategies to improve clinical and economic outcomes.

Upon completion of this activity, participants will be able to:

  • Outline the clinical and socioeconomic burdens of ovarian cancer and the goals of remission maintenance that can be addressed by clinical pathways

  • Explore the role of the DNA damage response (DDR) pathway in tumor suppression and describe how mutations in DDR genes lead to tumor proliferation

  • Compare and contrast safety and efficacy outcomes from recent pivotal trials on PARP inhibitors in ovarian cancer, with a close look at the maintenance setting

  • Examine the role of PARP inhibitors as a first-line maintenance therapy for patients with advanced ovarian cancer

  • Define strategies for anticipating, recognizing, and managing adverse events of PARP inhibitor therapy in patients with ovarian cancer

  • Apply methods to enable optimal cost management of PARP inhibitors to be realized by multiple ovarian cancer stakeholders including managed care organizations

     

Faculty: Richard T. Penson, MD, MRCP
Associate Professor of Medicine Harvard Medical School
Clinical Director Medical Gyn Onc at Massachusetts General Hospital
IRB Chair, Dana-Farber / Harvard Cancer Center
 

Disclosure:

Dr. Penson has served as a researcher for Genetech, Inc., AstraZeneca, Eisai, Amgen, Inc, Vascular Biogenics Ltd, Array BioPharma, and Sanofi-Aventis US LLC. Dr. Penson has held positions on the scientific advisory boards for Genetech, Inc., AstraZeneca, Eisai, Inc, Amgen, Inc., Clovis Oncology, Vascular Biogenetics Ltd, AbbVie, Tesaro, Merck & Co, Sutro BioPharma, Mersana Therapeutics, New Line. His presentation has been reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no financial relationships with ineligible companies to disclose.
Jeremy Williams has no financial relationships with ineligible companies to disclose.
Jacqueline Cole, RN, MS, CMCN has no financial relationships with ineligible companies to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by educational grants from
GlaxoSmithKline, Merck Sharp & Dohme Corp., and AstraZeneca

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue